CD274 and metastatic neoplasm: Taken into consideration the fact that the PD-1 and PD-L1 inhibitors have an objective response rate of around 20–40% in a variety of metastatic tumor types, several clinical trials have investigated the effect of combined therapy including anti-PD-1 therapy and chemotherapy.